JP2023541007A5 - - Google Patents

Info

Publication number
JP2023541007A5
JP2023541007A5 JP2023515155A JP2023515155A JP2023541007A5 JP 2023541007 A5 JP2023541007 A5 JP 2023541007A5 JP 2023515155 A JP2023515155 A JP 2023515155A JP 2023515155 A JP2023515155 A JP 2023515155A JP 2023541007 A5 JP2023541007 A5 JP 2023541007A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
acetylglucosamine
approximately
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048991 external-priority patent/WO2022051575A2/en
Publication of JP2023541007A publication Critical patent/JP2023541007A/ja
Publication of JP2023541007A5 publication Critical patent/JP2023541007A5/ja
Pending legal-status Critical Current

Links

JP2023515155A 2020-09-04 2021-09-03 ウイルス感染処置のための化合物および方法 Pending JP2023541007A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063074602P 2020-09-04 2020-09-04
US63/074,602 2020-09-04
US202163142669P 2021-01-28 2021-01-28
US63/142,669 2021-01-28
PCT/US2021/048991 WO2022051575A2 (en) 2020-09-04 2021-09-03 Compounds and methods for treating viral infection

Publications (2)

Publication Number Publication Date
JP2023541007A JP2023541007A (ja) 2023-09-27
JP2023541007A5 true JP2023541007A5 (cg-RX-API-DMAC10.html) 2024-09-12

Family

ID=80491477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515155A Pending JP2023541007A (ja) 2020-09-04 2021-09-03 ウイルス感染処置のための化合物および方法

Country Status (7)

Country Link
US (1) US20230346816A1 (cg-RX-API-DMAC10.html)
EP (1) EP4208137A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023541007A (cg-RX-API-DMAC10.html)
CA (1) CA3194024A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023002667A (cg-RX-API-DMAC10.html)
TW (1) TW202228730A (cg-RX-API-DMAC10.html)
WO (1) WO2022051575A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202239417A (zh) * 2021-01-29 2022-10-16 艾米爾 E 哈森 預防病毒感染之方法
US20260191887A1 (en) * 2022-04-21 2026-07-09 Therapeutikos, Inc. Methods of treating inflammation
GB2628963A (en) * 2023-02-08 2024-10-16 Univ Of Lincoln Formulations and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533776A (zh) * 2003-03-27 2004-10-06 中国人民解放军第三军医大学 N-乙酰氨基葡萄糖在制备用于治疗病毒或细菌感染所致的局部损伤和全身症状的药物中的应用
CA2608651A1 (en) * 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
JP5522640B2 (ja) * 2009-10-15 2014-06-18 独立行政法人産業技術総合研究所 シアリルラクトサミン系、シアリルルイスx系のシアル酸とフコース含有新規糖鎖化合物
JP5807895B2 (ja) * 2011-02-17 2015-11-10 学校法人慶應義塾 Hcvrna複製抑制剤
EP2696680B1 (en) * 2011-04-15 2018-11-28 Marine Polymer Technologies, Inc. Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers
CN107281199A (zh) * 2017-07-27 2017-10-24 吉林省始祖生物波医学研究院有限公司 N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物

Similar Documents

Publication Publication Date Title
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
JP3701870B2 (ja) 末梢血管疾患治療のための9−デオキシ−2’,9−α−メタノ−3−オキサ−4,5,6−トリノール−3,7−(1’,3’−インターフェニ
US6335021B1 (en) Composition for controlling mood disorders in healthy individuals
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
Zosel et al. Severe lactic acidosis after an iatrogenic propylene glycol overdose
JP2022521233A5 (cg-RX-API-DMAC10.html)
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20030195255A1 (en) Method for treating hepatic encephalopathies
JP2023548429A5 (cg-RX-API-DMAC10.html)
Hall et al. Rapid deterioration in patients with parkinsonism following tryptophan‐pyridoxine administration
US20200085849A1 (en) Methods and compositions for improving sleep
HUT56496A (en) Process for producing pharmaceutical compositions comprising buspirone, suitable for treating apnoea arising during sleep
JPH03170475A (ja) 抑うつ症治療剤
CN108472375A (zh) 中重度流感的治疗方法
JP6454436B1 (ja) ペマフィブラートを含有する医薬
EP1121110B1 (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
JPH06172187A (ja) 筋ジストロフィー症治療薬
JP2021509671A5 (cg-RX-API-DMAC10.html)
HUT56497A (en) Process for producing pharmaceutical compositions comprising pyrimidinyl piperazine derivatves, suitable for treating apnoea arising during sleep
Kim et al. The alternative of oral sedation for pediatric dental care
Ehgartner et al. Hemodynamic instability following intentional nadolol overdose
Sathaporn et al. A Rare Cause of Refractory Vasodilatory Shock Due to Calcium Channel Blocker Toxicity from Drug-Drug Interaction Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) And Manidipine
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
RU2457834C1 (ru) Способ лечения метаболического синдрома